Are current disease‐modifying therapeutics in multiple sclerosis justified on the basis of studies in experimental autoimmune encephalomyelitis?
Journal of neurochemistry, 2010•Wiley Online Library
J. Neurochem.(2010) 115, 829–844. Abstract The precise aetio‐pathology of multiple
sclerosis remains elusive. However, important recent advances have been made and
several therapies have been licensed for clinical use. Many of these were developed,
validated or tested in the animal model, experimental autoimmune encephalomyelitis (EAE).
This systematic review aims to assess whether the current disease modifying treatments and
those that are the closest to the clinic are justified on the basis of the results of EAE studies …
sclerosis remains elusive. However, important recent advances have been made and
several therapies have been licensed for clinical use. Many of these were developed,
validated or tested in the animal model, experimental autoimmune encephalomyelitis (EAE).
This systematic review aims to assess whether the current disease modifying treatments and
those that are the closest to the clinic are justified on the basis of the results of EAE studies …
J. Neurochem. (2010) 115, 829–844.
Abstract
The precise aetio‐pathology of multiple sclerosis remains elusive. However, important recent advances have been made and several therapies have been licensed for clinical use. Many of these were developed, validated or tested in the animal model, experimental autoimmune encephalomyelitis (EAE). This systematic review aims to assess whether the current disease modifying treatments and those that are the closest to the clinic are justified on the basis of the results of EAE studies. We discuss some aspects of the utility and caveats of EAE as a model for multiple sclerosis drug development.
Wiley Online Library